Trial · NCT04939311
Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial
NCT04939311, Phase 1, Phase 2, Withdrawn, Priscilla Hsue, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial. Trials, record NCT04939311. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04939311
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial
- NCT number
- NCT04939311
- Status
- Withdrawn
- Phases
- Phase 1, Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Priscilla Hsue, MD
- Conditions
- Inflammation, HIV Infection, Cardiovascular Disease
- Interventions
- VB-201, Placebo
- First posted
- 2021-06-25
- Last updated
- 2022-09-15
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Target-to-background ratio (TBR) | 1 year (Baseline and Week 52) | Change in Target-to-background ratio (TBR) from baseline to follow-up study at 52 weeks as assessed by Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) |
| Secondary | Change in high sensitivity C-reactive protein (hs-CRP) in mg/L | 1 year (Change from baseline to week 24 and baseline to week 52) | Change in hs-CRP from baseline to week 24 and baseline to week 52 as measured by blood collection |
| Secondary | Change in Interleukin-6 (IL-6) in pg/mL | 1 year (Change from baseline to week 24 and baseline to week 52) | Change in IL-6 from baseline to week 24 and baseline to week 52 as measured by blood collection |
| Secondary | Change in soluble cluster of differentiation (sCD163) ng/mL | 1 year (Change from baseline to week 24 and baseline to week 52) | Change in sCD163 from baseline to week 24 and baseline to week 52 as measured by blood collection |
| Secondary | Change in Lipoprotein (a) [Lp(a)] in mg/dL | 1 year (Change from baseline to week 24 and baseline to week 52) | Change in Lp(a) from baseline to week 24 and baseline to week 52 as measured by blood collection |
| Secondary | Change in Lipoprotein-associated Phospholipase A2 (Lp-PLA2) in ng/mL | 1 year (Change from baseline to week 24 and baseline to week 52) | Change in Lp-PLA2 from baseline to week 24 and baseline to week 52 as measured by blood collection |
| Secondary | Change in D-Dimer (ng/mL) | 1 year (Change from baseline to week 24 and baseline to week 52) | Change in D-Dimer from baseline to week 24 and baseline to week 52 as measured by blood collection |
| Secondary | Change in Markers of Immune Activation | 1 year (Change from baseline to week 24 and baseline to week 52) | Change in Co-expression of HLA-DR/CD38 on T-cells from baseline to week 24 and baseline to week 52 as measured by blood collection |
| Secondary | Change in Monocyte Activation | 1 year (Change from baseline to week 24 and baseline to week 52) | Change in Co-expression of CD14/CD16 on Monocytes from baseline to week 24 and baseline to week 52 |
| Other | Change in non-calcified plaque progression | 1 year (Baseline and Week 52) | Change in non-calcified plaque progression from baseline to week 52 as assessed by Coronary Computed Tomography Angiography (Coronary CTA) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04939311
GET https://conductscience.org/api/trials/v1/NCT04939311/registered